VCG
TEVA icon

Vantage Consulting Group’s Teva Pharmaceuticals TEVA Stock Holding History

Vantage Consulting Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,108
Closed -$20K – 1415
2020
Q4 		$20K Buy
+2,108
New +$20.2K ﹤0.01% 877

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Vantage Consulting Group's TEVA Position: Q1 2021 in Review

Vantage Consulting Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 2,108 shares — an estimated $20K sold.

Vantage Consulting Group first reported a position in TEVA in Q4 2020 and held it in 1 quarter. The position peaked at $20K in Q4 2020. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Vantage Consulting Group reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 2,108 Teva Pharmaceuticals shares in Q1 2021, an estimated $20K.
  • Vantage Consulting Group first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Teva Pharmaceuticals position peaked at $20K in Q4 2020.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.